Speculation surrounding a potential merger between GlaxoSmithKline and AstraZeneca has gained traction as GSK’s leadership undergoes a transition. Analysts recently suggested that the appointment of Luke Miels as GSK’s new
Speculation surrounding a potential merger between GlaxoSmithKline and AstraZeneca has gained traction as GSK’s leadership undergoes a transition. Analysts recently suggested that the appointment of Luke Miels as GSK’s new






